Compare · RECT vs TMO
RECT vs TMO
Side-by-side comparison of Rectitude Holdings Ltd (RECT) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- RECT operates in Consumer Discretionary, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $197.88B, about 10128.6x RECT ($19.5M).
- Over the past year, RECT is down 74.3% and TMO is up 31.4% - TMO leads by 105.6 points.
- TMO has been more active in the news (7 items in the past 4 weeks vs 4 for RECT).
- TMO has more recent analyst coverage (25 ratings vs 0 for RECT).
- Company
- Rectitude Holdings Ltd
- Thermo Fisher Scientific Inc
- Price
- $1.21-1.63%
- $532.16-2.05%
- Market cap
- $19.5M
- $197.88B
- 1M return
- -11.03%
- +12.59%
- 1Y return
- -74.26%
- +31.37%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 4
- 7
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest RECT
- Director Huang Dong was granted 17,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD., increasing direct ownership by 3% to 517,000 units (SEC Form 4)
- Director Ang Siew Sang was granted 14,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD. (SEC Form 4)
- Director Aw Victor was granted 11,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD. (SEC Form 4)
- CHIEF FINANCIAL OFFICER Chan Kah Chun was granted 10,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD. (SEC Form 4)
- Rectitude Holdings Ltd Secures Additional AIMS System Orders for Major Infrastructure and Residential Projects Across Singapore
- Rectitude Holdings Ltd Ramps up Supply Chain and Fleet Capacity Amid Surging Singapore Construction Demand
- SEC Form S-8 POS filed by Rectitude Holdings Ltd
- Rectitude Holdings Announces Renaming of Growth Strategy to "Rectitude Succession Bridge" and Strategic Collaboration with INOS Pte. Ltd. and G & L Hardware Marketing Pte. Ltd.
- Rectitude Holdings Secures Over S$10 Million in AIMS Contract Orders Amid Surging Demand for Green Energy Solutions
- SEC Form 3 filed by new insider Zhang Jian
Latest TMO
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- Bernstein resumed coverage on Thermo Fisher with a new price target
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target